Alison Jones | CEO & Founder
Quoiden

Alison Jones is a pharmacist and Founder & CEO of Quoiden, LLC, a digital health company advancing a novel, consent-driven approach to rare disease identification and patient engagement through family-network outreach. With over 25 years of experience in pharmacy, Alison began her career as a pharmacy technician and intern before advancing to staff pharmacist and ultimately Pharmacy Manager at Rite Aid, where she led operations, regulatory compliance, and patient care services for over a decade. Her clinical background and leadership experience provided a strong foundation in healthcare delivery, patient safety, and systems management. From 2017 to 2024, Alison served as a Healthcare Project Coordinator for the Jane Wright Earl Descendants OTC Deficiency Project, a large-scale, family-driven initiative focused on identifying individuals at risk for ornithine transcarbamylase (OTC) deficiency. Through this work, she developed and refined a groundbreaking model that integrates genealogy and genetics to enable privacy-respecting outreach to at-risk individuals across extended family networks. In July 2024, Alison founded Quoiden to scale this innovative approach into a secure digital platform that empowers individuals to build their own family trees, understand inherited risk, and access genetic counseling and testing—while enabling sponsors to engage with de-identified populations in a compliant and ethical manner. Alison’s work focuses on identifying individuals at risk for inherited conditions who remain undetected through traditional healthcare pathways. Her approach combines family-network insights, patient empowerment, and consent-driven data use to enable earlier awareness and responsible engagement in genetic services and research. Quoiden operationalizes this approach through a secure digital platform that enables individuals to build their own family connections. As these networks develop, patterns of inherited risk emerge, creating a consent-driven pathway to education, genetic services, and research participation. She is currently leading the development of Quoiden’s platform and collaborating with partners across telehealth, laboratory services, and rare disease research to bring this model to scale.